Pharmafile Logo

OPEN Health at the World Orphan Drug Conference USA

August 12, 2020 |  

Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !

Our Director of Rare Disease, Gavin Jones, is looking forward to his conversation with Emily Reuben (m.Crossley) and Betsy Bogard at #WODCUSA2020! He values the opportunity to speak to people at the front line of efforts to bring gene therapies to patients living with a rare disease and is sure the audience will do too. They will be sharing their thoughts based on the core themes of education and value demonstration that OPEN Health recently shared in a white paper.

This demonstrating our commitment to leading the conversation on how effective healthcare communications, and tools that enable them, can lead to faster and sustained patient access to gene and other advanced therapies. We brought together experience and capabilities from across our practices to develop broad thinking on ‘Succeeding with Star Wars Medicine – translating the science and value of gene therapy to key stakeholders’. The thinking is based on three key foundations:

  • Leading a patient first approach
  • Communicating the science
  • Demonstrating Value
Pink divider

Please find a short video of our Director of Rare Disease, Gavin Jones, describing why we have invested in this white paper and what you can expect from our recommendations.

Pink divider

To arrange a virtual presentation to discuss the findings and to receive a copy of the white paper please contact: gavinjones@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

Spotlight interview: 15 minutes on digital in medical communications

Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

Generating data on long-term outcomes with gene and other advanced therapies

Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

Spotlight interview: 15 minutes on insights and market research in pharma

Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...

Patient journey mapping: exploring the clinical and the emotional journey

By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...

OPEN Health announces the integration of Pharmerit International into the group

OPEN Health has today announced the integration of Pharmerit International, a global leader in health economics and outcomes research (HEOR), into its group of companies.

OPEN Health mobilised to support outcomes with gene and other advanced therapies

Harnessing the power of collaborations to bring real insights and improve outcomes

Spotlight interview: 15 minutes on PR in pharma

Vicky Bramham, Managing Director, OPEN Health takes 15 minutes to answer some key questions on PR discipline.

OPEN Health PBC recognised as No. 1 independent creative agency

We’re No.1! PMLive have named OPEN Health Patient & Brand Communications as the no.1 independent creative healthcare agency. The aim of the PMLive Top 10 lists is to highlight those...